Research Article

ERRγ, a Novel Biomarker, Associates with Pathoglycemia of Endometrial Cancer to Predict Myometrial Invasion

Yao Tong, Meimei Huang, Lili Chen, Huifang Lei, Hao Lin, Xiaodan Mao, Pengming Sun

1Department of Gynecology, Fujian Maternity and Child Health Hospital College of Clinical Medicine for Obstetrics & Gynecology and Pediatrics, Fujian Medical University, Fuzhou 350001, China
2Department of Gynecology, Fujian Obstetrics and Gynecology Hospital, Fuzhou 350001, China
3Reproductive Center, Fujian Maternity and Child Health Hospital College of Clinical Medicine for Obstetrics & Gynecology and Pediatrics, Fujian Medical University, Fuzhou 350001, China
4Laboratory of Gynecologic Oncology, Fujian Maternity and Child Health Hospital College of Clinical Medicine for Obstetrics & Gynecology and Pediatrics, Fujian Medical University, Fuzhou 350001, China
5Key Laboratory of Women and Children’s Critical Diseases Research, Fujian Maternity and Child Health Hospital College of Clinical Medicine for Obstetrics & Gynecology and Pediatrics, Fujian Medical University, Fuzhou 350001, China
6School of Medical Technology and Engineering, Fujian Medical University, No. 88 Jiaotong Road, Fuzhou 350004, China
7National Health Commission Key Laboratory of Technical Evaluation of Fertility Regulation for Non-human Primate, Jinjishan Road, Fuzhou 350005, China

Correspondence should be addressed to Xiaodan Mao; maodan1985@fjmu.edu.cn and Pengming Sun; fmsun1975@fjmu.edu.cn

Received 20 February 2022; Revised 25 April 2022; Accepted 5 May 2022; Published 21 June 2022

Copyright © 2022 Yao Tong et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

We aim to investigate the correlation between the expression of estrogen-related receptor γ (ERRγ) and endometrial cancer (EC) progression and to evaluate the potential of ERRγ as a new biomarker for EC diagnosis. We analyzed the ERRγ expression profile and the correlation with the corresponding clinical characteristics of EC samples from The Cancer Genome Atlas (TCGA), the Clinical Proteomic Tumor Analysis Consortium (CPTAC) databases, and the International Cancer Genome Consortium (ICGC) databases. Immunohistochemical (IHC) analysis was conducted on tissue samples, and enzyme-linked immunosorbent assay (ELISA) was used in serum samples to detect the levels of ERRγ. The diagnostic performance of ERRγ proteins was assessed using the receiver operating characteristic (ROC). ERRγ showed notably higher expression in EC tissues than in normal endometrium tissues (P < 0.001), which was consistent with the result of TCGA. Overexpression of ERRγ was significantly associated with deep myometrial invasion of EC (P = 0.004), and fasting blood glucose (FBG) was higher in EC patients with deep myometrial invasion than in those with superficial myometrial invasion (P = 0.04). Further analysis using ELISA showed that the serum ERRγ level was positively correlated with FBG (R = 0.355, P < 0.001). ERRγ is overexpressed in EC and may be involved in regulating glucose metabolism and promoting myometrial invasion of EC. In addition, the area under the ROC curve (AUC) for ERRγ was 0.834, in distinguishing EC patients from healthy individuals, presented 84.0% and 80.0% sensitivity and specificity, respectively, and serum ERRγ has a good diagnostic performance in distinguishing EC patients from healthy people and may be a promising noninvasive biomarker in EC.

1. Introduction

The incidence of endometrial cancer (EC) is increasing year by year, and it has become the first cancer of the female reproductive tract in the world [1]. Myometrial invasion in advanced EC is closely related to poor prognosis [2]. However, the mechanisms involved in the invasion and metastasis of malignant tumors are still unclear. Patients usually seek medical attention for abnormal uterine bleeding, which is found to be EC by pap-smear, curettage pathology, or hysteroscopy. Due to the lack of specific markers, it is of great significance to find reliable and
valuable biomarkers for early identification and diagnosis of EC.

Abnormal glucose metabolism is a common feature often observed in patients with EC [3]. Accumulating evidence indicates that hyperglycemia is associated with poor prognosis of EC [4,5]. Recently, studies have found that the nuclear receptor estrogen-related receptor γ (ERRγ), as a metabolism-related gene, is widely involved in the regulation of several key enzymes in cell glucose metabolism, lipid metabolism, and amino acid metabolism [6]. ERRγ is related to abnormal glucose metabolism, such as insulin resistance, and other pathological states and participates in the occurrence and development of diseases with abnormal glucose metabolism [7]. ERRγ is highly expressed in diabetic patients with poor blood glucose control [8] and is abnormally expressed in a variety of metabolism-related diseases, including malignant tumors, and involved in the occurrence and development of cancer [9,10].

This study aimed to investigate the relationship between ERRγ and EC and glucose metabolism to evaluate the role of ERRγ as a biomarker for the diagnosis of EC.

2. Materials and Methods

2.1. Data Acquisition and Processing. We explored mRNA expression of ERRγ from The Cancer Genome Atlas (TCGA) database, including 546 EC and 35 normal endometrial tissue samples. We analyzed the expression of ERRγ mRNA in patients with different histological subtypes and stages. Clinical Proteomic Tumor Analysis Consortium (CPTAC) analysis of the UALCAN portal (http://ualcan.path.uab.edu/analysis-prot.html) was used to identify the protein expression level of ERRγ in UCEC (uterine corpus endometrial carcinoma). In addition, another dataset from the International Cancer Genome Consortium (ICGC) data portal (https://icgc.org/) was used to assess survival differences.

2.2. Patients. The medical records of 525 EC patients treated in Fujian Maternity and Child Health Hospital College of Clinical Medicine for Obstetrics & Gynecology and Pediatrics, Fujian Medical University from January 2012 to December 2018 were studied retrospectively. The exclusion criteria were as follows: (1) patients with a history of other malignancies; (2) patients with nonepithelial cancers of the uterus, such as carcinosarcoma; (3) patients treated with chemotherapy, radiotherapy, or hormone therapy before surgery; (4) patients missing clinical pathology data or with an unclear diagnosis; and (5) patients who did not agree for further analysis of their pathological tissue. Healthy controls were from those who had undergone curettage for other reasons such as endometrial polyps, adenomyosis, leiomyomas, hyperplasia, and hemorrhages due to congenital and acquired coagulopathies, ovarian dysfunction, and disorders of the local endometrial hemostasis mechanism with normal organ structure. Healthy controls received adequate screening and excluding for endometrial lesions or other types of malignancies and other disease during the same period. This study was approved by the Ethics Committee of Fujian Maternity and Child Health Hospital College of Clinical Medicine for Obstetrics & Gynecology and Pediatrics, Fujian Medical University (No. YCXM20-01) and performed in compliance with the Declaration of Helsinki. Informed consent was obtained from all participants included in the study.

2.3. Sample Preparation. For the discovery phase, we collected endometrial cancer tissue from 525 EC patients who had retained tissue samples during the last 7 years. Excluding unqualified samples and those without informed consent, 79 cases of endometrial carcinoma were eventually included. Among them, stage I and II patients (n = 63) accounted for 78.5% of the total cases and endometrioid adenocarcinoma; nonendometrioid adenocarcinoma was about 4:1, consistent with the epidemiological distribution [11,12]. Patients with normal endometrial pathology (n = 32) were collected during the same period. All tissue samples were collected during the surgery. Immunohistochemistry (IHC) was used to detect the expression of ERRγ in tissue chip samples. For the validation phase, serum samples from 50 EC patients from January 2021 to December 2021 were collected and paired with 50 healthy individuals. There were 41 patients in the early stage, and the stage distribution was consistent with the epidemiological characteristics (Figure 1). All serum samples were collected two days before surgery, and ERRγ protein was evaluated by ELISA, which were entirely separated from the discovery set samples. All methods were carried out in accordance with relevant guidelines and regulations set out below.

2.4. Immunohistochemistry. To examine the expression of ERRγ in tissue, we performed a tissue microarray constructed by Shanghai Zhuoli Biotechnology Co., Ltd (Zhuoli Biotechnology Co., Shanghai, China). Rabbit polyclonal anti-ERRγ (ab49129, Abcam) were used. Two pathologists independently evaluated the quantitation of immunostaining for ERRγ, who were blinded to patient details. The expression of ERRγ in tumor parenchyma was semi-quantified by the immunoreactivity score (IR score) based on intensity and heterogeneity. The IR score was determined as the sum of heterogeneity and intensity. Intensity of staining was scored as 0 (negative), 1 (low), 2 (medium), and 3 (high). Area extent of staining was scored as 0 (0% stained), 1 (1–25% stained), 2 (26–50% stained), and 3 (51–100% stained). The final score was determined by multiplying the intensity scores with area extent and ranged from 0 to 9. Final scores (intensity score × percentage score) < 6 were considered as low and ≥ 6 were high expression.

2.5. Serum. ELISA. Blood samples were collected and centrifuged at 1500g for 10 min. Serum samples were stored at −70°C until the day of the analysis. The serum level of ERRγ was assessed by using a solid phase sandwich enzyme linked immunosorbent assay (ELISA) kit (cat. #JL48961; Jianglei Inc., Shanghai, China), following the manufacturers’ protocol. The optical density of each well was then read at 450 nm using a microplate reader. Serum levels of ERRγ were calculated from a standard curve based on reference standards.
2.6. **Statistical Analysis.** In this study, ERRγ expression was compared to different groups using the chi-square or Fisher’s exact test, when appropriate. Student’s t-test was used to compare continuous variables in two groups. Pearson correlation analysis was used to evaluate the correlations between continuous variables. Survival rates were calculated using the Kaplan–Meier estimator. Receiver-operating characteristic (ROC) curves were used to evaluate the diagnostic value of ERRγ. The ERRγ cut-off value was calculated using the Youden index. All statistical analyses were performed using SPSS 22.0 (IBM, Chicago, IL, USA) and GraphPad Prism version 8.0 software (GraphPad Software, Inc., La Jolla, CA, USA). All P values in the statistical analysis were two-tailed. P < 0.05 was considered statistically significant.

3. **Results**

3.1. **Expression of ERRγ in TCGA Database and the CPTAC Database.** As shown in Figures 2(a)–2(c), the mRNA expression profiles retrieved from TCGA revealed that the expression of ERRγ was significantly higher in EC than the normal sample (P < 0.001). There was no difference in both International Federation of Gynecology and Obstetrics (FIGO) stages and histological subtypes (P > 0.05). The CPTAC database showed that ERRγ expression was higher in the deep myometrial invasion depth group than in the superficial myometrial invasion depth group, but the difference was not statistically significant (P > 0.05; Figure 2(d)). The expression of ERRγ in G2-G3 group was higher than that in G1 group (P < 0.05; Figure 2(e)), while there was no statistical significance in ERRγ expression in different stage groups (P > 0.05; Figure 2(f)).

3.2. **ERRγ Is Highly Expressed in EC Tissue.** We analyzed the expression of ERRγ in 79 cases of EC tissue samples and 32 cases of healthy controls by IHC (Figure 2(g)). ERRγ was more highly expressed in EC tissues than in normal endometrial tissue (P < 0.001). Among 79 cases of EC samples, 59 samples showed high ERRγ expression (Figure 2(h)). In addition, we analyzed the differences in the expression of
Expression of ESRRG in UCEC based on Sample types

(a) Normal (n=35)  TCGA samples

Expression of ESRRG in UCEC based on individual cancer stages

(b) Primary tumor (n=546) Stage1 (n=341) Stage2 (n=52) Stage3 (n=124) Stage4 (n=29) TCGA samples

Expression of ESRRG in UCEC based on Histological subtypes

(c) Endometrioid (n=409) Serous (n=115) Mixed serous and endometrioid (n=22) TCGA samples

The expression of ERRγ

(d) ≥ 1/2MI<1/2MI

Grade 1 Grade 2-3

(e) P=0.537

High Low

Myometrial invasion

(f) P=0.004

Figure 2: Continued.
ERRγ in tumor tissues with different clinical features (Figures 2(i)–2(m)). We observed that high ERRγ expression is associated with deep myometrial invasion ($P = 0.004$), and there was no statistical significance in the expression of ERRγ among different clinical stages, pathological types, and lymph node metastatic status groups ($P > 0.05$).

### 3.3. Overexpression of ERRγ Significantly Correlates with Deep Myometrial Invasion.

We analyzed the correlation between the expression of ERRγ and immunohistochemical markers in EC tissues (Table 1). The results showed that the high expression rate of ERRγ in the vimentin-positive group was higher than that in the vimentin-negative group (76.8% vs. 23.2%), and Spearman correlation analysis showed a significant positive correlation between ERRγ and vimentin ($R = 0.368$, $P = 0.001$). There was no statistical correlation between ERRγ and ER, PR, PTEN, P53, and Ki67 ($P > 0.05$). In addition, the expressions of vimentin and Ki67 were different in different myometrial invasion groups ($P = 0.018$, $P = 0.042$), and there was no significant difference in the expressions of ER, PR, PTEN, and P53 in different myometrial invasion groups ($P > 0.05$).

### 3.4. Risk Factors for Deep Myometrial Invasion in EC.

According to the depth of myometrial invasion, patients with EC were divided into two groups (Table 2). Comparing the clinical information of the two groups, it was found that the age, FBG, and CA125 were higher in the deep myometrial invasion group ($P'0.001$, $P = 0.001$, and $P = 0.009$), but there were no statistically significant differences in BMI, triglyceride, cholesterol, and other parameters between the two groups ($P > 0.05$). Age, FBG, and CA125 were risk factors for deep myometrial invasion in EC, and FBG and CA125 were still associated with the risk of deep myometrial invasion after adjustment for age (OR = 1.281, 95% CI = 1.102–1.490, $P = 0.001$ OR = 1.002, 95% CI = 1.000–1.004, $P = 0.019$; Table S1). In addition, our results showed that the high expression of ERRγ in EC tissue was associated with higher FBG and CA125 (P'0.001, $P = 0.004$; Figures 3(a) and 3(b)), while there was no statistical correlation with TC, TG, CA15-3, and CA19-9 (all $P > 0.05$; Figures 3(c)–3(f)). The level of FBG in the deep myometrial invasion group was higher than that in the superficial myometrial invasion group ($P = 0.040$; Figure 3(g)), while the difference of CA125 in different myometrial invasion groups was not statistically significant in the 79 EC patients ($P = 0.177$; Figure 3(h)).

### 3.5. Prognostic Value of the ERRγ Expression Level in EC Tissue.

The ICGC database showed that there was no statistical difference in overall survival and disease-free survival between donors with and without ERRγ mutations ($P > 0.05$; Figures 4(a) and 4(b)). We followed up 79 cases of endometrial cancer with cancer tissue for nearly 7 years, including 1 case of loss to follow-up, and only 4 cases of death among 78 patients. There was no statistically significant difference in the survival rate between patients with high and low expression of ERRγ protein in tissues ($P > 0.05$; Figure 4(c)).

### 3.6. The Expression Levels of ERRγ in Serum.

Next, the serum ERRγ level was determined in the cohort of 50 EC patients and 50 control samples from healthy people by ELISA. The results showed that serum levels of ERRγ was significantly higher in EC patients (2.156 ± 1.254 ng/mL) than in healthy controls (0.994 ± 0.879 ng/mL, $P < 0.001$; Figure 5(a)). No significant association was shown between serum ERRγ levels and depth of myometrial invasion ($P = 0.954$; Figure 5(b)).

### 3.7. Diagnostic Value of the Serum ERRγ Level in EC.

We further sought to evaluate the diagnostic ability of serum ERRγ in EC. A receiver operating characteristic (ROC) curve was used to evaluate the diagnostic value of the serum ERRγ level to further determine whether ERRγ could serve as a noninvasive biomarker (Figure 6; Table S2). The area under the ROC curve (AUC) for ERRγ, CA125, and FBG was 0.834, 0.648, and 0.601, respectively, in distinguishing EC patients from healthy individuals, and the ERRγ cutoff value was 1.050 ng/mL with a sensitivity of 84.0% and a specificity of 80.0%. Moreover, in the stratified study of patients with
myometrial invasion depth groups. Of the different FBG levels, the AUC of ERR was 0.882, and the sensitivity of ERR was increased by 4.2% in the FBG ≥5.56 mmol/L group. When ERR and other indicators were combined to diagnose EC, the AUC of ERR/CA125 was 0.861, and the predictive performance of this combination was improved (Youden index = 0.680, P < 0.001). These data demonstrate the potential of serum ERR as a relevant test for EC diagnosis.

Table 1: Correlation between expression of ERR, myometrial invasion depth, and immunohistochemical markers in EC.

| Markers | ER expression (n%) | Myometrial invasion depth (n%) |
|---------|-------------------|-------------------------------|
|         | Low (n) | High (n) | P value | Low (n) | High (n) | P value |
| ER      | Negative | 0 (0.0) | 9 (15.3) | 0.102 | 4 (16.6) | 5 (9.1) | 0.443 |
| PR      | Positive | 20 (100.0) | 50 (84.7) | 0.057 | 5 (21.7) | 5 (9.1) | 0.128 |
| Vimentin | Negative | 11 (61.1) | 13 (23.2) | 0.003** | 3 (12.5) | 30 (60.0) | 0.018* |
| PTEN    | Positive | 7 (38.9) | 43 (76.8) | 0.332 | 6 (66.7) | 13 (50.0) | 0.460 |
| P53     | Negative | 5 (35.7) | 11 (52.4) | 0.495 | 9 (37.5) | 25 (46.3) | 0.470 |
| Ki67    | Positive | 7 (36.8) | 27 (45.8) | 0.332 | 8 (33.3) | 32 (58.2) | 0.042* |

ER: estrogen; PR: progesterone receptor. *P < 0.05; **P < 0.01.

Table 2: Clinical data comparison of EC patients with different myometrial invasion depth groups.

| Variable | n | ≥1/2 | n | <1/2 | P value |
|----------|---|------|---|-----|---------|
| Age (years) | 141 | 56.96 ± 9.32 | 384 | 52.44 ± 8.08 | <0.001** |
| BMI (kg/m²) | 112 | 24.56 ± 3.33 | 299 | 24.50 ± 3.46 | 0.875 |
| FBG (mmol/L) | 141 | 5.82 ± 1.59 | 383 | 5.34 ± 1.07 | 0.001** |
| TG (mmol/L) | 140 | 1.57 ± 1.14 | 383 | 1.57 ± 0.95 | 0.960 |
| TC (mmol/L) | 140 | 4.95 ± 1.09 | 382 | 4.98 ± 0.92 | 0.772 |
| HDL (mmol/L) | 116 | 1.41 ± 0.27 | 345 | 1.41 ± 0.38 | 0.969 |
| LDL (mmol/L) | 86 | 2.96 ± 0.98 | 259 | 2.87 ± 0.74 | 0.384 |
| CA125 (U/mL) | 139 | 96.90 ± 246.89 | 369 | 36.91 ± 173.12 | 0.009** |
| CA15-3 (U/mL) | 132 | 14.69 ± 20.36 | 362 | 11.07 ± 11.36 | 0.055 |
| CA19-9 (U/mL) | 128 | 207.43 ± 1020.83 | 325 | 71.40 ± 670.46 | 0.165 |
| SCC (μg/L) | 111 | 1.49 ± 1.29 | 290 | 1.25 ± 1.07 | 0.065 |
| AFP (ng/mL) | 130 | 3.47 ± 7.64 | 348 | 2.72 ± 1.41 | 0.268 |
| CEA (ng/mL) | 130 | 2.16 ± 1.46 | 354 | 2.05 ± 1.91 | 0.554 |

Notes: BMI: body mass index; FBG: fasting blood glucose; TG: triglyceride; TC: total cholesterol; HDL: high-density lipoprotein; LDL: low-density lipoprotein. *P < 0.05; **P < 0.01.

3.8. Correlation between Serum Levels of ERRy and FBG. Our results showed that serum ERRy levels in subjects with FBG ≥5.56 mmol/L were significantly higher than those with FBG <5.56 mmol/L (P = 0.006; Figure 5(c)). Then, we observed a significant positive correlation between serum ERRy levels and FBG in EC patients and healthy controls, with a correlation coefficient of 0.355 (P < 0.001; Figure 5(d)). However, there was no significant correlation between serum ERRy levels and CA125 and age (P = 0.135, P = 0.602; Figures 5(e) and 5(f)). These findings provided further evidence to support that the serum ERRy levels were associated with FBG levels.

4. Discussion

In this study, we found ERRy is overexpressed in both tissues and serum of EC patients. The expression level of ERRy in tissues was significantly correlated with myometrial invasion in EC patients, and the level of ERRy was positively correlated with the FBG level. In addition, ROC analysis showed that serum ERRy has a good diagnostic performance in distinguishing EC patients from healthy people. These results suggest that ERRy may be involved in regulating glucose metabolism and promoting myometrial invasion of EC and may be a noninvasive biomarker source for endometrial cancer detection and progression monitoring.

The prognostic factors of EC have been studied in detail. The most important factors include FIGO stage, myometrial invasion, histological subtypes and grades, and lymphatic invasion [2]. Among them, myometrial invasion is an important manifestation of invasion and metastasis of malignant
tumor, while two recent systematic reviews and a meta-analysis showed that both deep myometrial invasion and lymphovascular space invasion have prognostic value independent of TCGA signature, as well as age and adjuvant treatment [13, 14]. ERRγ is one of the members of the orphan nuclear receptor [15]. With the in-depth research in recent years, it has been found that the expression of ERRγ is abnormal in a variety of malignant tumors and plays a role in the development of tumors [9]. In breast cancer, ERRγ is usually overexpressed and upregulated after acquisition of tamoxifen resistance, suggesting that ERRγ plays a promoting role in cancer. In prostate cancer [16], selective ERα/γ reverse agonist SLU-PP-1072 can inhibit the Warburg effect and induce apoptosis of prostate cancer cells [17]. Sun Y et al. found that ERRγ was positively expressed in EC cells, and ERRγ could promote the proliferation of estrogen-dependent EC cells by activating the AKT-ERK1/2 signal pathway [18]. Hua T et al. reported that ERRγ could promote the expression of E-cadherin and participate in the migration and metastasis of EC cells [19]. The results showed that ERRγ was closely related to the progress of EC. In this study, bioinformatics analysis was carried out based on TCGA database, and IHC results confirmed that ERRγ was highly expressed in EC, and our data indicated that ERRγ was closely related to the deep myometrial invasion of EC, which was an invasion-related indicator with potential prognostic value. However, the prognostic relationship between ERRγ and different pathological and molecular types remains to be further studied.
In recent years, various clinical studies have found that EC is associated with metabolic disorders, including obesity, diabetes, and metabolic syndrome [20]. EC patients are often accompanied by systemic metabolic disorders, and hyperglycemia is the main clinical feature, which is related to poor outcome [4, 21, 22]. Our clinical data analysis found that the depth of myometrial invasion of EC was correlated with FBG, suggesting that poor blood glucose status is closely related to the development of EC. At present, more and more evidence confirms that ERR\(_c\) plays a central role in metabolic genes and the regulation of cellular energy metabolism [23]. Previous studies have shown that ERR\(_c\) can bind and regulate a variety of glycolytic gene promoters such as hexokinase 2 (Hk2), Aldolase C (Aldo-C) enolase 1, and lactate dehydrogenase A (LDHA) [24]. O-GlcNAcylation of ERR\(_c\) serves as a major signal to promote hepatic gluconeogenesis [25]. These results indicate that ERR\(_c\) is involved in maintaining glucose homeostasis in vivo, and the imbalance of glucose metabolism—high level of glycolysis—is one of the characteristics of tumor cell metabolism [26, 27]. However, there are few studies on the relationship between ERR\(_c\) and abnormal glucose metabolism in tumor. Our results suggest that ERR\(_c\) is significantly correlated with blood glucose in EC, and it is likely that ERR\(_c\) is involved in regulating blood glucose in EC and promoting myometrial invasion.

Current biomarkers for EC metastasis, such as immunohistochemical markers ER and PR, have great limitations and lack specificity. With the development of molecular typing of endometrial cancer, these old markers are no longer clinically useful; it is of great significance to find a new biomarker. Raffone A et al. reported that metabolomics may be suitable for a noninvasive diagnosis and screening of EC, offering the possibility to predict tumor behavior and pathological characteristics [28]. Several metabolites such as homocysteine, phospholipase-

![Graphs](image_url)

**Figure 4:** (a–b) The relationship between ERR\(_c\) mutation and prognosis in the ICGC database. (c) Kaplan–Meier (KM) survival curves of EC patients with different ERR\(_c\) expressions.
**Figure 5:** (a) Serum levels of ERRγ in EC patients and healthy controls. (b) Serum levels of ERRγ in different myometrial invasion depth groups. (c) Serum levels of ERRγ in different serum FBG groups. (d–f) Correlation analysis between serum ERRγ and other indicators in EC patients and healthy controls. FBG: fasting blood glucose.

**Figure 6:** Continued.
A2, and lysophospholipase-D, may be useful for diagnosis, screening, and prediction of tumor histotype, myometrial invasion, lymph vascular invasion, and cancer progression in patients with EC [28]. It is noteworthy that ERRγ, as a metabolism-related gene, is closely associated with tumor glucose metabolism and may be added to the list. ERRγ has good diagnostic performance in distinguishing EC patients from healthy people, with high sensitivity and specificity. ERRγ detection is not only suitable for tissue but also for serum, and with the increase of the expression level of tumor progression, it has the characteristics of tumor markers, which could have an extraordinary impact on the management of EC in the future.

Some shortcomings of this study should be acknowledged. First, the sample size in this study is relatively small, which might raise the bias of analysis. Second, it is necessary to further explore the internal mechanism of ERRγ regulating glucose metabolism and promoting myometrial invasion of EC. In addition, we only measured serum ERRγ levels in the validation phase; however, the comparative information of ERRγ expression in and out of cells could not be determined.

5. Conclusion

Collectively, ERRγ is overexpressed in EC and may be involved in regulating glucose metabolism and promoting myometrial invasion of EC. In addition, serum ERRγ has a good diagnostic performance in distinguishing EC patients from healthy people and may be a promising noninvasive biomarker in EC.

Data Availability

Data used to support the findings of this study are available from the corresponding author upon request.

Conflicts of Interest

The authors declare that there are no conflicts of interest that could be perceived as prejudicing the impartiality of the research reported.

Acknowledgments

The authors thank all the women who participated in the study and gratefully acknowledge assistance from the staff at the Laboratory of Gynecologic Oncology, Fujian Maternity and Child Health Hospital. This study was supported by the Innovation Fund of Fujian Maternity and Child Health Hospital College of Clinical Medicine for Obstetrics & Gynecology and Pediatrics, Fujian Medical University (grant no. YCXM20-01).

Supplementary Materials

Table S1: logistic regression analysis of myometrial invasion in EC. Table S2: diagnostic value of ERRγ, CA125, and FBG for EC patients. (Supplementary Materials)

References

[1] R. L. Siegel, K. D. Miller, H. E. Fuchs, and A. Jemal, "Cancer Statistics," CA: A Cancer Journal for Clinicians, vol. 71, no. 1, pp. 7–33, 2021.
[2] P. Morice, A. Leary, C. Creutzberg, N. Abu-Rustum, and E. Darai, "Endometrial cancer," Lancet (London, England), vol. 387, no. 10023, pp. 1094–1108, 2016.
[3] F. L. Byrne, A. R. Martin, M. Kosasih, B. T. Caruana, and R. Farrell, "The role of hyperglycemia in endometrial cancer Pathogenesis," Cancers, vol. 12, no. 5, p. 1191, 2020.
[4] E. M. Ko, P. Walter, L. Clark et al., "The complex triad of obesity, diabetes and race in Type I and II endometrial cancers: prevalence and prognostic significance," Gynecologic Oncology, vol. 133, no. 1, pp. 28–32, 2014.
[5] M. A. Onstad, R. E. Schmandt, and K. H. Lu, “Addressing the role of obesity in endometrial cancer risk, prevention, and treatment,” *Journal of Clinical Oncology*, vol. 34, no. 35, pp. 4225–4230, 2016.

[6] E. Yoshihara, Z. Wei, C. S. Lin et al., “ERRy is required for the metabolic maturation of therapeutically functional glucose-responsive β cells,” *Cell Metabolism*, vol. 23, no. 4, pp. 622–634, 2016.

[7] J. J. Misra, D. K. Kim, and H. S. Choi, “ERRy: a Junior orphan with a Senior role in metabolism,” *Trends in Endocrinology and Metabolism*, vol. 28, no. 4, pp. 261–272, 2017.

[8] A. Soundararajan, P. Prabhu, V. Mohan, Y. Gibert, and M. Balasubramanyam, “Novel insights of elevated systemic levels of bisphenol-A (BPA) linked to poor glycemic control, accelerated cellular senescence and insulin resistance in patients with type 2 diabetes,” *Molecular and Cellular Biochemistry*, vol. 458, no. 1-2, pp. 171–183, 2019.

[9] J. H. Kim, Y. K. Choi, J. K. Byun et al., “Estrogen-related receptor γ is upregulated in liver cancer and its inhibition suppresses liver cancer cell proliferation via induction of p21 and p27,” *Experimental & Molecular Medicine*, vol. 48, no. 3, p. e213, 2016.

[10] Z. Ren, H. Yang, C. Wang, and X. Ma, “The effects of PGC-1α on the proliferation and energy metabolism of malignant endometrial cancer cells,” *OncoTargets and Therapy*, vol. 8, pp. 769–774, 2015.

[11] K. H. Lu and R. R. Broadus, “Endometrial cancer,” *New England Journal of Medicine*, vol. 383, no. 21, pp. 2053–2064, 2020.

[12] V. W. Setiawan, H. P. Yang, M. C. Pike et al., “Type I and II endometrial cancers: have they different risk factors?” *Journal of Clinical Oncology*, vol. 31, no. 20, pp. 2607–2618, 2013.

[13] A. Raffone, A. Travaglino, D. Raimondo et al., “Prognostic value of myometrial invasion and TCGA groups of endometrial carcinoma,” *Gynecologic Oncology*, vol. 162, no. 2, pp. 401–406, 2021.

[14] A. Raffone, A. Travaglino, D. Raimondo et al., “Lymphovascular space invasion in endometrial carcinoma: a prognostic factor independent from molecular signature,” *Gynecologic Oncology*, vol. 165, no. 1, pp. 192–197, 2022.

[15] V. Giguère, N. Yang, P. Segui, and R. M. Evans, “Identification of a new class of steroid hormone receptors,” *Nature*, vol. 331, no. 6151, pp. 91–94, 1988.

[16] S. Madhavan, Y. Gusev, S. Singh, and R. B. Riggins, “ERRy target genes are poor prognostic factors in Tamoxifen-treated breast cancer,” *Journal of Experimental & Clinical Cancer Research*, vol. 34, no. 1, p. 45, 2015.

[17] E. Schoepke, C. Billon, K. M. Haynes et al., “A selective ERRα/γ inverse agonist, SLU-PP-1072, inhibits the Warburg effect and induces apoptosis in prostate cancer cells,” *ACS Chemical Biology*, vol. 15, no. 9, pp. 2338–2345, 2020.

[18] Y. Sun, C. Wang, H. Yang, and X. Ma, “The effect of estrogen on the proliferation of endometrial cancer cells is mediated by ERRy through AKT and ERK1/2,” *European Journal of Cancer Prevention*, vol. 23, no. 5, pp. 418–424, 2014.

[19] T. Hua, X. Wang, S. Chi et al., “Estrogen-related receptor γ promotes the migration and metastasis of endometrial cancer cells by targeting S100A4,” *Oncology Reports*, vol. 40, no. 2, pp. 823–832, 2018.

[20] B. Trabert, N. Wentzensen, A. S. Felix, H. P. Yang, M. E. Sherman, and L. A. Brinton, “Metabolic syndrome and risk of endometrial cancer in the United States: a study in the SEER-medicare linked database,” *Cancer Epidemiology Biomarkers & Prevention*, vol. 24, no. 1, pp. 261–267, 2015.

[21] J. Ni, T. Zhu, L. Zhao et al., “Metabolic syndrome is an independent prognostic factor for endometrial adenocarcinoma,” *Clinical and Translational Oncology*, vol. 17, no. 10, pp. 835–839, 2015.

[22] C. M. Nagle, E. J. Crosbie, A. Brand et al., “The association between diabetes, comorbidities, body mass index and all-cause and cause-specific mortality among women with endometrial cancer,” *Gynecologic Oncology*, vol. 150, no. 1, pp. 99–105, 2018.

[23] Y. S. Kida, T. Kawamura, Z. Wei et al., “ERRs mediate a metabolic Switch Required for Somatic cell Reprogramming to Pluripotency,” *Cell Stem Cell*, vol. 16, no. 5, pp. 547–555, 2015.

[24] Q. Cai, T. Lin, S. Kamarajugadda, and J. Lu, “Regulation of glycolysis and the Warburg effect by estrogen-related receptors,” *Oncogene*, vol. 32, no. 16, pp. 2079–2086, 2013.

[25] J. Misra, D.-K. Kim, Y. S. Jung et al., “O-GlcNAcylation of orphan nuclear receptor estrogen-related receptor γ promotes hepatic gluconeogenesis,” *Diabetes*, vol. 65, no. 10, pp. 2835–2848, 2016.

[26] Y. Asgari, Z. Zabihinpour, A. Salehzadeh-Yazdi, F. Schreiber, and A. Masoudi-Nejad, “Alterations in cancer cell metabolism: the Warburg effect and metabolic adaptation,” *Genomics*, vol. 105, no. 5–6, pp. 275–281, 2015.

[27] P. P. Hsu and D. M. Sabatini, “Cancer cell metabolism: Warburg and beyond,” *Cell*, vol. 134, no. 5, pp. 703–707, 2008.

[28] A. Raffone, J. Troisi, D. Boccia et al., “Metabolomics in endometrial cancer diagnosis: a systematic review,” *Acta Obstetricia et Gynecologica Scandinavica*, vol. 99, no. 9, pp. 1135–1146, 2020.